The role of mass spectrometry in the study of non-enzymatic protein glycation in diabetes: an update.
Recent studies on non-enzymatic protein glycation are reviewed, and results are critically discussed. Advanced glycation end products (AGE) levels in the body reflect a balance between their formation and catabolism. AGE proteolysis leads to the formation of low-molecular-weight AGE (AGE peptides) that are normally excreted in urine. In the case of diabetic disease and/or renal failure, AGE peptides accumulate in plasma. Because of their high reactivity, these compounds have been thought to play a role in the progression of chronic complications. The structural identification of these compounds is particularly important, and a strategy has been designed for their possible definition. A series of experiments has been devoted to the study of the enzymatic degradation products of in vitro glycated human serum albumin (HSA). This approach, based on different MS methods (LC/ESI/MS, LC/ESI/FTMS, MALDI), led to the detection of the glycated peptides generated by digestion of HSA. A further study was devoted to the possible identification of the peptides identified in the glycated HSA digestion products in the plasma of diabetic and nephropatic subjects. No glycated HSA digestion products were found in plasma samples of the subjects under investigation even if clear differences were found among the LC runs from populations of healthy, diabetic, and nephropatic subjects. Parallel investigations were devoted to the evaluation of glyoxal and methylglyoxal-dicarbonyl compounds that originate at the intermediate stage of the Maillard reaction. This evaluation was performed in diabetic patients, before and after the achievement of good metabolic control, and in nephropatic patients subjected to peritoneal dialysis (PD). In the latter case, results indicated that these dicarbonyl compounds, already present in the dialysis fluids, show a decrease in plasma and in dialysis fluids; those data suggested their reaction at peritoneal membrane level.
Lapolla
Annunziata
A
Dipartimento di Scienze Mediche e Chirurgiche, Cattedra di Malattie del Metabolismo, Università di Padova, Padova, Italy.
Fedele
Domenico
D
Seraglia
Roberta
R
Traldi
Pietro
P
D015415:Biomarkers / Q000097:blood; D001798:Blood Proteins / Q000032:analysis*; D003920:Diabetes Mellitus / Q000175:diagnosis* / Q000378:metabolism*; D004798:Enzymes / Q000737:chemistry; D017127:Glycation End Products, Advanced / Q000032:analysis / Q000737:chemistry* / Q000378:metabolism*; D013058:Mass Spectrometry / Q000379:methods* / Q000639:trends*
D015415:Biomarkers; D001798:Blood Proteins; D004798:Enzymes; D017127:Glycation End Products, Advanced